



Fluid & Metering



Health & Science



Fire & Safety /  
Diversified

Third Quarter 2022 Earnings  
October 26, 2022



Trusted Solutions,  
Improving Lives™

# Agenda

IDEX Business Overview

Q3 2022 Financial Performance

Segment Performance

2022 Guidance Summary

Q&A



# Replay Information

- Dial toll-free: 877.660.6853
- International: 201.612.7415
- Conference ID: #13724804
- Log on to: [www.idexcorp.com](http://www.idexcorp.com)



# Cautionary Statement

## Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures

This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s full year 2022 outlook including expected organic sales growth, expected earnings per share and adjusted earnings per share, and the assumptions underlying these expectations, anticipated future acquisition behavior and capital deployment, availability of cash and financing alternatives, the intent to refinance or repay the 3.20% Senior Notes using the available borrowing capacity of the Revolving Facility, the anticipated timing of the closing of and the anticipated sources of funding for the Company’s acquisition of Muon Group and the anticipated benefits of the Company’s acquisitions, including the acquisitions of ABEL Pumps, L.P. and certain of its affiliates, Airtech, Nexsight, KZValve and Muon Group, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this presentation. The risks and uncertainties include, but are not limited to, the following: the impact of health epidemics and pandemics, including the COVID-19 pandemic, and the impact of related governmental actions, on the Company’s ability to operate its business and facilities, on its customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars, including Russia’s invasion of Ukraine and the global response to this invasion, which, along with the ongoing effects of the COVID-19 pandemic, could have an adverse impact on the Company’s business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain backlogs, including risks affecting component availability, labor inefficiencies and freight logistical challenges; market conditions and material costs; risks related to environmental, social and corporate governance (“ESG”) issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this presentation, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending September 30, 2022, which is available on our website.




# Business Update



*Trusted Solutions,  
Improving Lives™*



# IDEX Overview



## **Strong Third Quarter Results**

- Record sales, adjusted EPS, and free cash flow
- Organic sales growth of 15%
- Double-digit organic growth across all three segments



## **Executing Capital Deployment Strategy**

- Announced acquisition of Muon Group
- Portfolio optimization through divestiture of Knight LLC
- New operating leader to accelerate capital deployment



## **Driving Short-Term Execution with Excellence**

- Navigate choppy macro / supply chain
- Execute core operating approach
- Maintain operational rigor AND deploy capital



# Financials




*Trusted Solutions,  
Improving Lives™*

# IDEX Q3 2022 Financial Performance

(Dollars in millions, excl. EPS)


## Sales

+15% Organic\*




## Adjusted Earnings per Share\*

20% Increase




## Adjusted Operating Margin\*

60 bps increase



## Free Cash Flow\*

28% increase




**Strong Revenue, Profitability, and Earnings**





# Q3 2022 Adjusted Operating Income Walk

(Dollars in millions)



*Volume and Price-cost partly offset by growth investments and discretionary spend*



# IDEX Segment Performance



## Fluid & Metering Technology

Q3 Revenue \$308M / 37% of Total

- Stable Industrial market
- Strong Water & Ag markets
- Favorable Energy

Organic Orders V%*	2%
Organic Sales V%*	17%
Adj Op Margin vbps*	+250

Q3 2022 includes incremental impact of acquisition-related amortization of (80) bps\*



## Health & Science Technology

Q3 Revenue \$345M / 42% of Total

- Genetic sequencing strong
- Broadband/Fuel Cell wins
- Semiconductor share gain

Organic Orders V%*	(4%)
Organic Sales V%*	13%
Adj Op Margin vbps*	(70)



## Fire & Safety / Diversified

Q3 Revenue \$172M / 21% of Total

- Dispensing project deliveries
- Share gain in Auto / Energy
- Targeted growth within Rescue

Organic Orders V%*	0%
Organic Sales V%*	14%
Adj Op Margin vbps*	+70

\*This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending September 30, 2022, which is available on our website.

# 2022 Guidance Summary

		Fourth Quarter	Full Year	
		Current Guidance	Prior Guidance	Current Guidance
Revenue% vs. Prior Year	Organic*	~9%	~10%	~12%
Operating Margin%	Reported	~23.5%	~24%	~24%
Earnings per Share	Reported	\$1.75-\$1.80	\$7.19-\$7.29	\$7.75-\$7.80
	Adjusted*	\$1.92-\$1.97	\$7.88-\$7.98	\$8.04-\$8.09

## Other Modeling Items:

FX Impact on Sales	-5% -a)	-3% -b)	-4% -a)
Acquisition/Divestiture impact on Sales	3%	5%	5%
Corporate Costs	\$22 million	~\$80 million	~\$83 million
Tax Rate	21.0%	22.5%	~22.0%
Capital Expenditures		\$90+ million	~\$85 million
Free Cash Flow % of Adjusted Net Income		75-80%	75-80%

(a - Based on 9/30/2022 FX rate)

(b - Based on 6/30/2022 FX rate)

Earnings per share estimates exclude all future acquisitions and any future restructuring expenses



Trusted Solutions,  
Improving Lives™


# Appendix



*Trusted Solutions,  
Improving Lives™*

# Fluid & Metering Technologies

(Dollars in millions)



Q3 Sales Mix:	
Organic	17%
Acquisition/Divestiture	9%
FX	(4%)
Reported Sales	22%

## Q3 Highlights:

- Steady Industrial demand
- Strong Agriculture market with tailwind to Precision Ag applications
- Increasing Municipal Water project activity
- Incremental amortization related to the Nexsight and KZValve acquisitions unfavorably impacted adjusted operating margin by 80 basis points.
- Strong volume, productivity, and favorable price-cost driving margin expansion


*Strong growth and margin expansion*



# Health & Science Technologies


## Orders

-4% Organic\*




## Sales

+13% Organic\*



## Adjusted Operating Margin\*

-70 bps\*



Q3 Sales Mix:	
Organic	13%
Exit of COVID-19 testing application	6%
FX	<u>(5%)</u>
Reported Sales	14%

### Q3 Highlights:

- ❑ Strong Life Sciences, Analytical Instrumentation, Food & Pharma
- ❑ Continued wins in Genetic Sequencing, Broadband, and Fuel Cells
- ❑ Continued share gains in Semiconductor and Energy markets
- ❑ Volume leverage more than offset by discretionary/resource spend and lower productivity

*Strong growth enables reinvestment*




\*This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the three-month period ending September 30, 2022, which is available on our website.



# Fire & Safety / Diversified Products

(Dollars in millions)



Q3 Sales Mix:		
Organic		14%
FX		(6%)
Reported Sales		8%

## Q3 Highlights:

- ❑ BAND-IT strong Energy and Industrial and share gain in Automotive
- ❑ Dispensing delivery of North America project volume
- ❑ Strong adoption of E3 Rescue tool
- ❑ Fire continues to lag due to supply chain issues with OEMs but improved delivery, price, and favorable loose equipment sales
- ❑ Strong volume leverage partly offset by dilutive price-cost
- ❑ Price-cost improved in Q3 and expect further improvement into Q4

*Strong growth with price-cost tempering margin performance*



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure.  
(dollars in millions, except per share amounts)

## Reconciliation of the Change in Net Sales to Organic Net Sales

	Three Months Ended September 30, 2022			
	FMT	HST	FSDP	IDEX
<b>Change in net sales</b>	22%	14%	8%	16%
<b>- Net impact from acquisitions/divestitures</b>	9%	—%	—%	3%
<b>- Impact from foreign currency</b>	(4%)	(5%)	(6%)	(5%)
<b>- Impact from the exit of a COVID-19 testing application<sup>(1)</sup></b>	—%	6%	—%	3%
<b>Change in organic net sales</b>	17%	13%	14%	15%

(1) Represents the acceleration of previously deferred revenue of \$17.9 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application due to a shift in demand. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

## Reconciliations of Reported-to-Adjusted Gross Profit and Margin

	Three Months Ended September 30,	
	2022	2021
<b>Gross profit</b>	<b>\$ 381.8</b>	<b>\$ 311.6</b>
- Impact from the exit of a COVID-19 testing application <sup>(1)</sup>	(17.9)	—
+ Fair value inventory step-up charges	—	9.1
<b>Adjusted gross profit</b>	<b>\$ 363.9</b>	<b>\$ 320.7</b>
<b>Net sales</b>	<b>\$ 824.0</b>	<b>\$ 712.0</b>
- Impact from the exit of a COVID-19 testing application <sup>(1)</sup>	(17.9)	—
<b>Adjusted net sales</b>	<b>806.1</b>	<b>712.0</b>
<b>Gross margin</b>	<b>46.3%</b>	<b>43.8%</b>
<b>Adjusted gross margin</b>	<b>45.1%</b>	<b>45.0%</b>

(1) Represents the acceleration of previously deferred revenue of \$17.9 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure.  
(dollars in millions, except per share amounts)

## Reconciliation of Reported-to-Adjusted Operating Income and Margin

	Nine Months Ended September 30,									
	2022					2021				
	FMT	HST	FSDP	Corporat	IDEX	FMT	HST	FSDP	Corporat	IDEX
Reported operating income (loss)	\$ 257.8	\$ 255.7	\$ 124.0	\$(61.1)	\$ 576.4	\$ 195.4	\$ 213.0	\$ 126.5	\$(59.9)	\$ 475.0
+ Fair value inventory step-up charges	0.4	—	—	—	0.4	2.5	9.1	—	—	11.6
+ Restructuring expenses and asset impairments	1.7	0.1	1.0	—	2.8	4.8	1.7	0.1	2.0	8.6
- Net impact from the exit of a COVID-19 testing application <sup>(1)</sup>	—	(1.1)	—	—	(1.1)	—	—	—	—	—
+ Corporate transaction indemnity	—	—	—	—	—	—	—	—	3.5	3.5
Adjusted operating income (loss)	<u>\$ 259.9</u>	<u>\$ 254.7</u>	<u>\$ 125.0</u>	<u>\$(61.1)</u>	<u>\$ 578.5</u>	<u>\$ 202.7</u>	<u>\$ 223.8</u>	<u>\$ 126.6</u>	<u>\$(54.4)</u>	<u>\$ 498.7</u>
Net sales (eliminations)	\$ 879.5	\$ 986.2	\$ 508.3	\$ (2.8)	\$ 745.9	\$ 827.7	\$ 479.4	\$ (3.0)	\$	\$
- Impact from the exit of a COVID-19 testing application <sup>(1)</sup>	—	(17.9)	—	—	(17.9)	—	—	—	—	—
Adjusted net sales (eliminations)	<u>879.5</u>	<u>968.3</u>	<u>508.3</u>	<u>(2.8)</u>	<u>2,353.3</u>	<u>745.9</u>	<u>827.7</u>	<u>479.4</u>	<u>(3.0)</u>	<u>2,050.0</u>
Reported operating margin	29.3%	25.9%	24.4%	n/m	24.3%	26.2%	25.7%	26.4%	n/m	23.2%
Adjusted operating margin	29.6%	26.3%	24.6%	n/m	24.6%	27.2%	27.0%	26.4%	n/m	24.3%

(1) Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

## Reconciliation of Reported-to-Adjusted Net Income

	Three Months Ended September 30,	
	2022	2021
Reported net income attributable to IDEX	\$ 178.7	\$ 115.7
+ Restructuring expenses and asset impairments	—	3.2
+ Tax impact on restructuring expenses and asset impairments	—	(0.7)
+ Fair value inventory step-up charges	—	9.1
+ Tax impact on fair value inventory step-up charges	—	(2.0)
- Net impact from the exit of a COVID-19 testing application <sup>(1)</sup>	(1.1)	—
+ Tax impact on the exit of a COVID-19 testing application	0.3	—
- Gain on sale of business	(34.8)	—
+ Tax impact on gain on sale of business	5.5	—
+ Corporate transaction indemnity	—	(0.4)
+ Tax impact on Corporate transaction indemnity	—	0.1
+ Acquisition-related intangible asset amortization	17.0	16.2
+ Tax impact on acquisition-related intangible asset amortization	(3.7)	(3.7)
Adjusted net income attributable to IDEX	\$ 161.9	\$ 137.5

(1) Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure. (dollars in millions, except per share amounts)

## Reconciliation of Reported-to-Adjusted EPS

	Three Months Ended September 30,	
	2022	2021
Reported diluted EPS attributable to IDEX	\$ 2.36	\$ 1.51
+ Restructuring expenses and asset impairments	—	0.04
+ Tax impact on restructuring expenses and asset impairments	—	(0.01)
+ Fair value inventory step-up charges	—	0.12
+ Tax impact on fair value inventory step-up charges	—	(0.03)
- Net impact from the exit of a COVID-19 testing application <sup>(1)</sup>	(0.01)	—
+ Tax impact on the exit of a COVID-19 testing application	—	—
- Gain on sale of business	(0.46)	—
+ Tax impact on gain on sale of business	0.07	—
+ Corporate transaction indemnity	—	—
+ Tax impact on Corporate transaction indemnity	—	—
+ Acquisition-related intangible asset amortization	0.23	0.21
+ Tax impact on acquisition-related intangible asset amortization	(0.05)	(0.05)
Adjusted diluted EPS attributable to IDEX	\$ 2.14	\$ 1.79
Diluted weighted average shares outstanding	75.8	76.5

(1) Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.





# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure.  
(dollars in millions, except per share amounts)

## *Reconciliation of Cash Flows from Operating Activities to Free Cash Flow*

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Cash flows from operating activities	\$ 198.1	\$ 156.6	\$ 390.1	\$ 402.2
- Capital expenditures	16.3	14.9	48.0	45.5
Free cash flow	\$ 181.8	\$ 141.7	\$ 342.1	\$ 356.7



# Reconciliation of Non-GAAP Measures

This information reconciles non-GAAP measures (denoted with a \*) with the most directly comparable GAAP measure.  
(dollars in millions, except per share amounts)

## Reconciliation of Estimated 2022 EPS to Adjusted EPS Attributable to IDEX

	Guidance	
	Fourth Quarter 2022	Full Year 2022
<b>Estimated EPS attributable to IDEX</b>	\$1.75 - \$1.80	\$7.75 - \$7.80
+ Acquisition-related intangible asset amortization	0.22	0.87
+ Tax impact on acquisition-related intangible asset amortization	(0.05)	(0.19)
- Gains on sales of assets	—	(0.03)
+ Tax impact on gains on sales of assets	—	0.01
+ Restructuring expenses and asset impairments	—	0.04
+ Tax impact on restructuring expenses and asset impairments	—	(0.01)
- Gain on sale of business	—	(0.46)
+ Tax impact on gain on sale of business	—	0.07
- Net impact from the exit of a COVID-19 testing application <sup>(1)</sup>	—	(0.01)
+ Tax impact on the exit of a COVID-19 testing application	—	—
<b>Estimated adjusted EPS attributable to IDEX</b>	<b>\$1.92 - \$1.97</b>	<b>\$8.04 - \$8.09</b>

(1) Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application. Refer to the Exit of a COVID-19 Testing Application section in earnings release for further detail.

